Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2C19 | P33261 | 1/20 | 0.52 |
| ▸ | EPHX1 | P07099 | 2/20 | 0.44 |
| ▸ | CA12 | O43570 | 2/20 | 0.39 |
| ▸ | CA1 | P00915 | 2/20 | 0.39 |
| ▸ | CA2 | P00918 | 2/20 | 0.39 |
| ▸ | CA9 | Q16790 | 2/20 | 0.39 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
| ▸ | NAAA | Q02083 | 2/20 | 0.38 |
| ▸ | HTT | P42858 | 1/20 | 0.37 |
| ▸ | CYP19A1 | P11511 | 3/20 | 0.35 |
| ▸ | MMP1 | P03956 | 1/20 | 0.34 |
| ▸ | MMP9 | P14780 | 1/20 | 0.34 |
| ▸ | MMP12 | P39900 | 1/20 | 0.34 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.33 |
| ▸ | FABP7 | O15540 | 1/20 | 0.33 |
| ▸ | FABP5 | Q01469 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9485096 | 1.00 | CYP2C19 (0.52) | CYP2C19EPHX1CA12CA1CA2 | |
| SCHEMBL16086274 | 0.96 | CYP2C19 (0.47) | CYP2C19EPHX1CA12CA1CA2 | |
| SCHEMBL16086282 | 0.93 | CYP2C19 (0.48) | CYP2C19EPHX1CA12CA1CA2 | |
| SCHEMBL16086650 | 0.90 | CYP2C19 (0.47) | CYP2C19EPHX1CA12CA1CA2 | |
| SCHEMBL16086398 | 0.90 | CYP2C19 (0.47) | CYP2C19EPHX1CA12CA1CA2 | |
| SCHEMBL26939777 | 0.88 | CYP2C19 (0.44) | CYP2C19EPHX1CA12CA1CA2 | |
| SCHEMBL16086275 | 0.86 | CYP2C19 (0.43) | CYP2C19EPHX1CA12CA1CA2 | |
| SCHEMBL26939776 | 0.83 | CYP2C19 (0.41) | CYP2C19EPHX1CHRM3MAPTNAAA | |
| SCHEMBL16086283 | 0.83 | CYP2C19 (0.44) | CYP2C19EPHX1CA12CA1CA2 | |
| SCHEMBL1660666 | 0.82 | CYP2C19 (0.43) | CYP2C19EPHX1CA12CA1CA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2781522-A1 | OPTICALLY ACTIVE BISOXAZOLINE COMPOUND, ASYMMETRIC CATALYST, AND METHOD FOR PRODUCING OPTICALLY ACTIVE CYCLOPROPANE COMPOUND USING SAID CATALYST | Sumitomo Chemical Company, Limited (JP) | 2014-09-24 | — | — | EP | disclosed |
| EP-1642901-B1 | Novel erythromycin derivatives | PFIZER PROD INC (US) | 2007-10-31 | — | — | EP | disclosed |
| EP-1642901-A1 | Novel erythromycin derivatives | Pfizer Products Inc. (US) | 2006-04-05 | — | — | EP | disclosed |
| US-7015203-B2 | Erythromycin analogs and azalides, particularly ones with novel C-13 substituents; for treating bacterial and protozoa infections | PFIZER INC. (US) | 2006-03-21 | — | — | US | disclosed |
| EP-1602727-A2 | Novel erythromycins and process for their preparation | Biotica Technology Limited (GB) | 2005-12-07 | — | — | EP | disclosed |
| EP-0909327-B1 | ERYTHROMYCINS AND PROCESS FOR THEIR PREPARATION | BIOTICA TECH LTD (GB) | 2005-06-01 | — | — | EP | disclosed |
| US-6825171-B2 | MACROLIDE ANTIBIOTIC USEFUL IN THE TREATMENT OF A BROAD SPRECTRUM OF BACTERIAL INFECTIONS AND PROTOZOA INFECTIONS | PFIZER, INC. | 2004-11-30 | — | — | US | disclosed |
| US-20040092459-A1 | Novel macrolides | PFIZER INC. | 2004-05-13 | — | — | US | disclosed |
| US-20040067897-A1 | Novel erythromycin derivatives | PFIZER INC. | 2004-04-08 | — | — | US | disclosed |
| US-6472371-B1 | Macrolides | PFIZER, INC. | 2002-10-29 | — | — | US | disclosed |
| US-6437151-B2 | FERMENTATION; CULTURE PRODUCT | BIOTICA TECHNOLOGY LIMITED (GB) | 2002-08-20 | — | — | US | disclosed |
| US-20020004487-A1 | Novel erythromycins and process for their preparation | BIOTICA TECHNOLOGY LIMITED (GB) | 2002-01-10 | — | — | US | disclosed |
| US-20010016598-A1 | Fermenting suitable organisms such as saccharopolyspora erythraea in the presence of a carboxylic acid | LEADLAY PETER FRANCIS (GB) | 2001-08-23 | — | — | US | disclosed |
| US-6271255-B1 | USEFUL AS ANTIBACTERIAL AND ANTIPROTOZOAL AGENTS IN INFECTIONS IN MAMMALS, FISH, AND BIRDS | BIOTICA TECHNOLOGY LIMITED (GB) | 2001-08-07 | — | — | US | disclosed |
| EP-1044208-A1 | ERYTHROMYCIN DERIVATIVES | Pfizer Products Inc. (US) | 2000-10-18 | — | — | EP | disclosed |
| EP-1044207-A1 | NOVEL MACROLIDES | Pfizer Products Inc. (US) | 2000-10-18 | — | — | EP | disclosed |
| WO-1999035156-A1 | NOVEL MACROLIDES | PFIZER PRODUCTS INC. (US) | 1999-07-15 | — | — | WO | disclosed |
| WO-1999035157-A1 | NOVEL ERYTHROMYCIN DERIVATIVES | PFIZER PRODUCTS INC. (US) | 1999-07-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020004487-A1 | Novel erythromycins and process for their preparation | MRPL21, RPL13, RPS3A | CYP2C19 216/4885EPHX1 2719/4885CA12 3781/4885 |
| US-20040067897-A1 | Novel erythromycin derivatives | GIPR, MLNR, PGC | CYP2C19 270/4885EPHX1 1186/4885CA12 4241/4885 |
| US-20010016598-A1 | Fermenting suitable organisms such as saccharopolyspora erythraea in the presence of a carboxylic acid | COASY, RPL13, DCXR | CYP2C19 454/4885EPHX1 2513/4885CA12 1489/4885 |
| US-20040092459-A1 | Novel macrolides | CYP51A1, RPS12, AZI2 | CYP2C19 310/4885EPHX1 1316/4885CA12 2625/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.